Stevanato Group S.p.A. to Announce Third Quarter 2025 Financial Results on November 6, 2025
Stevanato Group S.p.A. (NYSE: STVN) (“Stevanato Group” or “the Company”), a leading global provider of drug containment, drug delivery, and diagnostic solutions serving the pharmaceutical, biotechnology, and life sciences industries, today announced that it will issue its financial results for the third quarter of 2025 before the U.S. financial markets open on Thursday, November 6, 2025, at 6:30 a.m. Eastern Time (ET).
Following the release, the Company will host a conference call and live webcast at 8:30 a.m. (ET) to discuss its results, review business highlights, and provide updates on strategic initiatives that are shaping its long-term growth trajectory.
Conference Call and Webcast Details
The Company’s conference call and webcast are scheduled for Thursday, November 6, 2025, at 8:30 a.m. (ET). Members of Stevanato Group’s executive management team — including the Chief Executive Officer, Chief Financial Officer, and other senior leaders — will review the Company’s financial and operational performance for the third quarter of 2025.
During the call, management will discuss key performance metrics, such as revenue growth, operating margins, profitability, and cash flow, as well as provide insight into strategic developments across its global business segments. The discussion will include an analysis of market trends, product innovation, customer partnerships, and supply chain initiatives that continue to strengthen the Company’s competitive position in the life sciences sector.
To support the discussion, management will reference a slide presentation that complements the financial results. The presentation will be made available on the morning of the call and can be accessed in the “Financial Results” section under the Investor Relations area of Stevanato Group’s corporate website at www.stevanatogroup.com/investors.
Pre-Registration for Conference Call Access
To ensure a seamless experience, Stevanato Group strongly encourages participants to pre-register for the conference call ahead of time. Those who pre-register will receive a unique conference passcode and personal identification number (PIN), allowing for immediate access to the call without having to wait for a live operator.
Participants can complete the registration process by visiting the following link:
👉 [STVN Conference Call Pre-Registration]
Once registered, participants will receive a confirmation email containing all the necessary information, including the dial-in details, passcode, and PIN. On the morning of the event, registered participants are encouraged to join the call at least ten minutes before the scheduled start time to ensure a smooth connection.
Webcast Access
For those preferring to join online, Stevanato Group will also offer a live, listen-only webcast of the conference call. The webcast can be accessed directly via the following link:
👉 [STVN Webcast]
The webcast will provide simultaneous access to both the live audio and slide presentation. Participants using this option will be able to follow management’s remarks in real-time.
A replay of the webcast will be made available shortly after the event concludes, and it will remain accessible on the Company’s website for a limited period. This feature ensures that investors, analysts, and other interested parties who are unable to attend the live event can review the discussion at their convenience.
Dial-In Numbers for Live Access
Participants who are unable to pre-register may still join the conference call by dialing in directly using one of the following numbers:
- Italy: +39 02 802 09 11
- United Kingdom: +44 1 212 818004
- United States: +1 718 705 8796
- United States Toll-Free: +1 855 265 6958
Callers are advised to dial in approximately ten minutes before the scheduled start of the call to allow time for connection and registration with the operator.
Q&A Participation
Participants who wish to ask questions during the conference call will be able to do so by joining through the HD webphone link at:
👉 https://hditalia.choruscall.com/?$Y2FsbHR5cGU9MiZpbmZvPWNvbXBhbnk=
This link will enable direct participation in the Q&A session following management’s prepared remarks. The question-and-answer portion of the call will provide an opportunity for analysts and investors to engage with Stevanato Group’s leadership team on topics such as business performance, market dynamics, and strategic outlook.
About Stevanato Group
Stevanato Group S.p.A. (NYSE: STVN) is a global leader in drug containment, drug delivery, and diagnostic solutions, serving customers across the pharmaceutical, biotechnology, and life sciences sectors. The Company provides integrated solutions that help ensure the safety, efficacy, and accessibility of medicines and healthcare products worldwide.
Founded in 1949 and headquartered in Piombino Dese, Italy, Stevanato Group has grown into one of the industry’s most trusted partners for high-quality drug packaging and delivery systems. Its comprehensive portfolio includes:
- Primary packaging solutions, such as glass vials, syringes, and cartridges designed for the containment of injectable pharmaceuticals.
- Advanced drug delivery devices, including auto-injectors and prefilled systems that improve patient safety and treatment adherence.
- Diagnostic and analytical solutions supporting next-generation medical technologies and point-of-care testing.
- Engineering and technical services that complement product offerings and ensure end-to-end value for customers.
The Company’s solutions are backed by decades of scientific expertise, precision manufacturing, and quality assurance, enabling global pharmaceutical and biotechnology companies to bring new therapies to market with confidence.
Stevanato Group operates a global network of manufacturing facilities and innovation centers, with locations across Europe, North America, and Asia. Its teams work collaboratively with customers to design and produce custom solutions that meet stringent regulatory requirements and evolving healthcare demands.
In addition to product excellence, the Company is deeply committed to sustainability and corporate responsibility. Stevanato Group continuously invests in technologies and processes that reduce environmental impact, enhance operational efficiency, and promote ethical business practices across its supply chain.
Strategic Outlook and Financial Focus
During the upcoming third-quarter results discussion, Stevanato Group’s management team will provide insights into the Company’s financial performance and strategic priorities. Expected discussion topics include:
- Revenue and Profitability Trends: An overview of organic growth across regions and product lines, highlighting key demand drivers.
- Operational Performance: Updates on cost optimization, manufacturing efficiency, and capital investment programs.
- Innovation and R&D Initiatives: Progress in developing new containment and delivery technologies that address emerging therapeutic modalities.
- Market Expansion: Strategic efforts to strengthen the Company’s presence in high-growth markets through customer partnerships and capacity expansions.
- Sustainability Goals: Updates on environmental and social commitments as part of Stevanato Group’s broader ESG (Environmental, Social, and Governance) strategy.
These initiatives reflect the Company’s unwavering commitment to advancing global healthcare through innovation, precision, and partnership.
This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. These statements are based on the current expectations and assumptions of Stevanato Group’s management and are subject to risks and uncertainties that could cause actual results to differ materially. Such factors include, but are not limited to, economic and market conditions, regulatory changes, competition, supply chain disruptions, and other factors detailed in the Company’s filings with the U.S. Securities and Exchange Commission (SEC).
Stevanato Group undertakes no obligation to update any forward-looking statements contained herein, whether as a result of new information, future events, or otherwise, except as required by law.
